Biomarkers for biopharma solutions consist of pharmacodynamic solutions, patient selection markers, assay development and bioinformatics / biostatistics consultancy. President and Managing Director of Almac’s Diagnostics ( division, Professor Paul Harkin said: With Biomarkers for biopharma, we have combined a range of key solutions which are ideally suited to growing biopharma companies. For these businesses, it is of crucial importance that they maximise the potential achievement of the drugs in their pipeline and the incorporation of a biomarker technique enables them to do this. Almac guideline and support businesses, enabling biomarker strategies that may maximise their medicines and business’s potential.. Almac’s solutions to support biopharma companies by adopting biomarker strategies Almac today announced the launch of Biomarkers for biopharma ( a range of solutions specifically made to meet the wants of the biopharma sector.1 / 3 had right ventricular dysfunction Approximately. There was a reduction in recurrences among sufferers with elevated NT-proBNP levels in the edoxaban group, which finding was backed by the evaluation of patients with correct ventricular dysfunction as assessed by means of computed tomography. The analysis design aimed to handle concerns that brand-new oral anticoagulants may confer an increased risk of bleeding among patients with renal impairment and lower body weight.12 We identified one fifth of individuals with these risk factors approximately.